Multiple Myeloma Diagnosis and Treatment

Diagnostic Criteria

The International Myeloma Society recommends using the CRAB criteria, which include hypercalcemia, renal insufficiency, anemia, and bone lesions, to diagnose multiple myeloma 1, 2
Hypercalcemia is defined as serum calcium >11.5 mg/dL, causing symptoms like fatigue, confusion, constipation, and thirst, according to the European Society for Medical Oncology 2, 3
Renal insufficiency is characterized by serum creatinine >2.0 mg/dL or creatinine clearance <40 mL/min, leading to kidney dysfunction, as stated by the American Society of Clinical Oncology 2
Anemia is defined as normochromic, normocytic with hemoglobin <10 g/dL or ≥2 g/dL below normal, resulting in weakness and fatigue, according to the National Comprehensive Cancer Network 2
Bone lesions are identified as lytic lesions, severe osteopenia, or pathologic fractures, causing bone pain and risk of fractures, as recommended by the International Myeloma Society 2

Serum and urine protein electrophoresis are essential for detecting and evaluating monoclonal (M-) component, as recommended by the American Society of Clinical Oncology 1, 4
Immunoglobulin quantification, including measurement of IgG, IgA, and IgM levels, is necessary for diagnosis, according to the European Society for Medical Oncology 1
Bone marrow examination, including aspiration and biopsy, is required to assess plasma cell infiltration (≥10% clonal plasma cells required for diagnosis), as stated by the National Comprehensive Cancer Network 1, 5
Skeletal imaging, including full skeleton X-ray survey, MRI, or CT, is necessary to evaluate lytic bone lesions, as recommended by the International Myeloma Society 1, 4

The European Society for Medical Oncology recommends induction therapy followed by high-dose therapy with autologous stem cell transplantation (ASCT) as the standard treatment for younger patients (<65 years or fit patients) 2
Induction regimens, such as bortezomib-dexamethasone, are superior to classical VAD regimen, according to the American Society of Clinical Oncology 2
Triple combinations, such as VTD (bortezomib, thalidomide, dexamethasone), show higher response rates, as recommended by the National Comprehensive Cancer Network 2
For elderly patients (≥65 years or transplant-ineligible), standard regimens include bortezomib, melphalan, prednisone (VMP) for 8-12 cycles, as stated by the International Myeloma Society 2, 5

The American Society of Clinical Oncology recommends long-term bisphosphonates (zoledronic acid or pamidronate) to reduce skeletal-related events 2, 5
Aggressive hydration with normal saline is necessary for hypercalcemia management, according to the European Society for Medical Oncology 5
Bisphosphonates are used for severe hypercalcemia, as recommended by the National Comprehensive Cancer Network 5
Bortezomib-based regimens can be safely administered without dose adjustment in patients with renal impairment, as stated by the International Myeloma Society 5

The National Comprehensive Cancer Network recommends initiating treatment promptly in patients meeting CRAB criteria to reduce morbidity and mortality 5
Immediate treatment is not recommended for patients with indolent/smoldering myeloma, according to the American Society of Clinical Oncology 2, 6

The presence of pleural effusion with lymphocyte predominance suggests myelomatous involvement, as indicated by the National Comprehensive Cancer Network 7
A prolonged PT >120 seconds is concerning and requires immediate correction before initiating therapy to prevent bleeding complications, according to the National Comprehensive Cancer Network 8

The National Comprehensive Cancer Network recommends bortezomib-based triplet therapy as the preferred initial treatment for patients with multiple myeloma, with a specific regimen of Bortezomib/Cyclophosphamide/Dexamethasone (VCD) 9, 8
Bortezomib can be safely administered without dose adjustment in renal impairment, as stated by the National Comprehensive Cancer Network 8
The use of melphalan-containing regimens (MPT, VMP) is not recommended initially, as they are stem cell toxic and may affect future transplant eligibility, according to the National Comprehensive Cancer Network and Annals of Oncology 7, 8

The subcutaneous route is preferred for bortezomib administration, as it reduces the risk of neuropathy, according to the National Comprehensive Cancer Network 9
Herpes zoster prophylaxis with acyclovir is mandatory when using bortezomib, as recommended by the National Comprehensive Cancer Network 8, 10
Dexamethasone dosing should be low-dose (40 mg weekly or 20 mg weekly if >75 years), as recommended by the National Comprehensive Cancer Network and Annals of Oncology 7, 9

Acyclovir prophylaxis is required for herpes zoster prevention with bortezomib, as stated by the National Comprehensive Cancer Network 8, 10
Pneumococcal vaccination (PCV13 followed by PPSV23) and influenza vaccination are recommended, according to the National Comprehensive Cancer Network 10
Full-dose aspirin is not recommended initially due to prolonged PT >120 seconds, but can be initiated once coagulopathy is corrected, as recommended by the National Comprehensive Cancer Network 9, 8

The patient's response to treatment should be assessed after 2 cycles, with repeat serum protein electrophoresis, immunofixation, and free light chains, as recommended by the National Comprehensive Cancer Network 8, 10
If the patient achieves good response and clinical improvement, stem cells can be collected after 3-4 cycles of induction, and autologous stem cell transplantation (ASCT) can be considered, according to the National Comprehensive Cancer Network 9, 8